|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
We tested whether eltrombopag, a thrombopoietin receptor agonist, might be effective in improving thrombocytopenia in lower-risk myelodysplastic syndromes and severe thrombocytopenia.
|
28162984 |
2017 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
In rare cases in which thrombocytopenia is the main clinical problem leading to clinically significant bleeding events, thrombopoietin receptor analogues may alleviate bleeding, increase platelet counts, and rarely lead to trilineage responses.
|
29222293 |
2017 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Thrombopoietin Receptor Agonist Use for Immune Thrombocytopaenia.
|
30646404 |
2019 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Thrombopoietin receptor agonists were given to 10 patients but did not shorten the duration of thrombocytopenia, reduce severe bleeding, or early death.
|
28910610 |
2017 |
|
Thrombocytopenia
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Thrombopoietin receptor agonists and risk of portal vein thrombosis in patients with liver disease and thrombocytopenia: A meta-analysis.
|
29958825 |
2019 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Usefulness of thrombopoietin receptor agonists for persistent clinically relevant thrombocytopenia after allogeneic stem cell transplantation.
|
29956377 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Thrombopoietin receptor (TPO-R) agonists, such as eltrombopag, represent a novel approach for the treatment of chemotherapy-induced thrombocytopenia.
|
22967017 |
2012 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Avatrombopag, an orally administered, small-molecule thrombopoietin receptor (c-Mpl) agonist, is currently in clinical development for the potential treatment of severe thrombocytopenia in patients with chronic liver disease undergoing an elective procedure.
|
28339166 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Described also is a comparative summary of the different aspects of five currently available therapies targeting TPO-R or SYK for the treatment of thrombocytopenia.
|
31226783 |
2019 |
|
Thrombocytopenia
|
0.400 |
CausalMutation
|
phenotype |
CLINVAR |
Diagnostic high-throughput sequencing of 2396 patients with bleeding, thrombotic, and platelet disorders.
|
31064749 |
2019 |
|
Thrombocytopenia
|
0.400 |
AlteredExpression
|
phenotype |
BEFREE |
In conclusion, we identified a C-terminal AML1 mutation that leads to a decrease in Mpl receptor expression, providing a potential explanation for thrombocytopenia in this FPD/AML pedigree.
|
15741216 |
2005 |
|
Thrombocytopenia
|
0.400 |
GeneticVariation
|
phenotype |
LHGDN |
Congenital amegakaryocytic thrombocytopenia: clinical and biological consequences of five novel mutations.
|
17666371 |
2007 |
|
Thrombocytopenia
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Our results indicate that c-mpl gene mutations are not a common cause of thrombocytopenia in TAR syndrome.
|
9827898 |
1998 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Pathogenesis and management of inherited thrombocytopenias: rationale for the use of thrombopoietin-receptor agonists.
|
23636669 |
2013 |
|
Thrombocytopenia
|
0.400 |
GeneticVariation
|
phenotype |
LHGDN |
Functional analysis of single amino-acid mutations in the thrombopoietin-receptor Mpl underlying congenital amegakaryocytic thrombocytopenia.
|
18422784 |
2008 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
ELT is an agonist at Thrombopoietin receptor, used in treatment of thrombocytopenia.
|
30507954 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Taken together, our findings indicate that, given its favourable pharmacological characteristics, hetrombopag may represent a new, orally active, small-molecule TPOR agonist for patients with thrombocytopenia.
|
30156363 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The thrombopoietin receptor agonist romiplostim improves exposure to chemotherapy in patients with glioblastoma experiencing temozolomide-induced thrombocytopenia.
|
31586022 |
2019 |
|
Thrombocytopenia
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Congenital amegakaryocytic thrombocytopenia (CAMT) is caused by the loss of thrombopoietin receptor-mediated (MPL-mediated) signaling, which causes severe pancytopenia leading to bone marrow failure with onset of thrombocytopenia and anemia prior to leukopenia.
|
23908116 |
2013 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
RGD |
Decreased prothrombotic effects of pegylated recombinant human megakaryocyte growth and development factor in thrombocytopenic state in a rat thrombosis model.
|
15670044 |
2005 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Lusutrombopag (S-888711), an oral small-molecule thrombopoietin receptor (TPOR) agonist, has gained first approval as a drug to treat thrombocytopenia of chronic liver disease in patients undergoing elective invasive procedures in Japan.
|
29274361 |
2018 |
|
Thrombocytopenia
|
0.400 |
GeneticVariation
|
phenotype |
BEFREE |
Use of a thrombopoietin receptor agonist in von Willebrand disease type 2B (p.V1316M) with severe thrombocytopenia and intracranial hemorrhage.
|
27885890 |
2017 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Preliminary clinical evidence suggests that thrombopoietin receptor agonists (TPO-RAs) with an established use in the treatment of certain acquired thrombocytopenias are well tolerated and provide clinical benefits in patients with some forms of HTP.
|
29956472 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
Avatrombopag is an oral thrombopoietin receptor agonist that has been recently approved for treating thrombocytopenia in chronic liver disease patients needing invasive procedures.
|
30203841 |
2018 |
|
Thrombocytopenia
|
0.400 |
Biomarker
|
phenotype |
BEFREE |
The clinical course suggests that 2 factors, including overproduction of interleukin 6 and autoimmune-mediated thrombocytopenia via thrombopoietin receptor, may have contributed to the pathogenesis of TAFRO syndrome in this patient.
|
29626596 |
2018 |